HOME >> BIOLOGY >> NEWS
Once weekly ENBREL significantly reduced rheumatoid arthritis pain, inflammation & improved function

THOUSAND OAKS, Calif., and COLLEGEVILLE, Pa., June 19, 2003 - Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced that patients receiving ENBREL(R) (etanercept) 50 mg once weekly for the treatment of active rheumatoid arthritis (RA) in a new clinical study experienced significant improvements in function and pain that were comparable to those receiving the currently approved dose (25 mg twice weekly), and significantly better than those receiving placebo. The data were presented at the European League Against Rheumatism (EULAR) Annual Congress of Rheumatology in Lisbon, Portugal.

The multi-center, double-blind, placebo-controlled study randomized 434 patients based on a 4:3:1 allocation to receive either ENBREL 50 mg (2 x 25 mg doses) once weekly, ENBREL 25 mg twice weekly, or placebo for eight weeks. The primary endpoint, a 20 percent improvement in signs and symptoms of RA (known as an ACR 20 response) after eight weeks, was achieved by 50 percent of patients treated once weekly with ENBREL, 49 percent of patients treated twice weekly with ENBREL and 19 percent of patients in the placebo group. Patients' functional status was assessed using the Health Assessment Questionnaire (HAQ). In addition, patient-reported measures assessing global status and pain were evaluated.

At week eight, improvement in HAQ was comparable for patients receiving either ENBREL dose, and significantly better than patients receiving placebo.

The average improvement from baseline in pain as reported by patients with ENBREL once weekly (33.4%) and ENBREL twice weekly (27.0%) was comparable, and higher than placebo (-19.3%). Average improvement from baseline in patient global scores showed similar results with ENBREL once weekly (26.8%), ENBREL twice weekly (26.7%) versus placebo (0.2%).

Adverse events, such as injection site reactions, infections, and headache, were similar to those reported in previous clinical tr
'"/>

Contact: Rebecca Hamm, Amgen
805-447-3872
Porter Novelli
20-Jun-2003


Page: 1 2 3 4

Related biology news :

1. ENBREL provided rapid and significant relief for psoriasis patients in second pivotal study
2. ENBREL rapidly, significantly improved back pain, mobility, function in ankylosing spondylitis
3. ENBREL combo therapy inhibits joint damage progression, offers significant RA symptom relief
4. ENBREL is first therapy approved for psoriatic arthritis
5. New Phase 2 study shows ankylosing spondylitis patients respond to ENBREL (etanercept)
6. Phase 3 psoriatic arthritis data for ENBREL (etanercept) announced at a national scientific meeting
7. Rare mutations can significantly increase risk factor for heart disease
8. Cancer health risk significantly underestimated by EPAs ambient model estimates
9. Double mastectomies significantly lower risk of breast cancer in women who are genetically at risk
10. HAART therapy significantly prolongs survival in AIDS patients with central nervous system lymphoma
11. Cognitive abilities increase significantly with time in most prematurely born children

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/5/2018)... , ... December 03, 2018 , ... ... Aesthetics , an emerging leader in the distribution and marketing of cutting-edge aesthetic ... growth, projecting $20MM in sales for 2018. Cartessa’s success can be attributed ...
(Date:12/5/2018)... DIEGO (PRWEB) , ... December 04, 2018 , ... ... leverage Fastec’s extensive expertise and existing IP in the development of innovative solutions ... has been integrated into diverse systems from microfluidics to industrial machinery and instrumentation, ...
(Date:11/27/2018)... ... 2018 , ... PulseEd™ uses researched technology, published in the Journal of ... flow to the penis. Regular and unimpeded blood flow to the blood vessels of ... function. The recorded results of SWT (sound wave therapy), indicated that almost 80% of ...
Breaking Biology News(10 mins):
(Date:11/13/2018)... ... November 13, 2018 , ... Renowned Honolulu veterinarian, Dr. Patrick Leadbeater, has ... Kauai. Dr. Leadbeater, of Kahala Pet Hospital on Oahu, is a ... began traveling to the island of Kauai on an almost weekly basis to perform ...
(Date:11/13/2018)... , ... November 13, 2018 , ... , Park Systems, ... in China. With the increasingly growing demand for AFM technology in China, Park Systems ... communities by opening an office in Beijing equipped with Park AFM. , The Grand ...
(Date:11/9/2018)... ... November 08, 2018 , ... IC System, one of ... approach to increasing recovery rates by creating a comprehensive contact strategy for each ... developed by NLP Logix, a Jacksonville, Florida-based AI solutions company, and leveraged the ...
(Date:11/6/2018)... and TAHOE, Nev. (PRWEB) , ... November 06, ... ... to their native mobile app for clinical trial data collection and management. ... Now, iPhone users with compatible generation devices can quickly and easily sign in ...
Breaking Biology Technology:
Cached News: